Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Docetaxel extravasation causing significant delayed tissue injury.

J Raley1, J P Geisler, T E Buekers

  • 1Division of Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA.

Gynecologic Oncology
|August 6, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An economic analysis of cisplatin alone versus cisplatin doublets in the treatment of women with advanced or recurrent cervical cancer.

European journal of gynaecological oncology·2016
Same author

Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX 2) immunostaining in ovarian cancer.

European journal of gynaecological oncology·2016
Same author

Cyclin E is overexpressed by clear cell carcinomas of the endometrium and is a prognostic indicator of survival.

European journal of gynaecological oncology·2015
Same author

Polyarteritis nodosa of the vagina mimicking vaginal carcinoma.

Journal of lower genital tract disease·2015
Same author

A case of severe hidradenitis suppurativa contributing to a death and a review of the literature.

Journal of lower genital tract disease·2015
Same author

Robotically-assisted laparoscopic radical parametrectomy and radical vaginectomy.

European journal of gynaecological oncology·2012

Docetaxel extravasation can cause severe, delayed tissue injury, even when administered peripherally. This case highlights the potential for significant toxicity and the importance of monitoring for adverse events during chemotherapy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Docetaxel, a taxane chemotherapy agent, is generally considered to have a low risk of tissue injury upon extravasation.
  • Current clinical practice guidelines do not typically mandate central venous access for docetaxel administration due to this perceived low risk.

Observation:

  • A 71-year-old female receiving docetaxel and carboplatin for recurrent ovarian cancer experienced extravasation of docetaxel into the dorsum of her left hand.
  • Delayed toxicity, including erythema, pain, blistering, and decreased function, manifested 6-7 days post-infusion.
  • Conservative management led to complete resolution of skin changes and return of function within 4 weeks.

Findings:

  • This case demonstrates that docetaxel can cause significant, delayed-onset, grade 4 tissue toxicity following extravasation from a peripheral intravenous site.

Related Experiment Videos

  • The severity and delayed presentation of the toxicity challenge the existing understanding of docetaxel extravasation risks.

    • Implications:

    • Clinicians should maintain a high index of suspicion for docetaxel-induced tissue injury, even with peripheral administration.
    • Enhanced patient monitoring and awareness of potential delayed adverse events are crucial for managing chemotherapy extravasations.
    • Further research may be warranted to fully characterize the risk profile of docetaxel extravasation and inform best practice guidelines.